Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03645408 · ClinicalTrials.gov registry record · Phase 1
The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers
A Phase 1 study, sponsored by Boston Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03645408 is a Phase 1 study that was terminated before completion, run by Boston Medical Center. The registered enrollment target is 8 participants.
The verdict
NCT03645408, a Phase 1 study, was terminated before completion, sponsored by Boston Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
A double-blind, randomized, placebo-controlled, crossover design trial was used to test the effect of exenatide on alcohol self-administration and craving following a priming dose of alcohol. The specific objective of this research was to determine whether exenatide has effects on alcohol consumption.
Interventions
- OTHER Sham injection
- DRUG Exenatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-05-02 |
| Est. Completion | 2021-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03645408
The ClinicalTrials.gov registry entry for NCT03645408 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham injection is the first listed.
NCT03645408 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03645408 about?
NCT03645408 is a clinical study titled "The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers". A double-blind, randomized, placebo-controlled, crossover design trial was used to test the effect of exenatide on alcohol self-administration and craving following a priming dose of alcohol. The specific objective of this research was to determine whether exenatide has effects on alcohol consumptio...
What is the current status of trial NCT03645408?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2019-05-02. Estimated completion is 2021-07-01.
What interventions are being tested in trial NCT03645408?
The interventions under investigation include: Sham injection (OTHER), Exenatide (DRUG).
Who is sponsoring clinical trial NCT03645408?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.